ClinicalTrials.gg
CompletedNCT07134231Updated Feb 6, 2026

Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ Model

A Phase 3 interventional study of Fluoride free toothpaste in a chalk base and Fluoride Toothpaste in Demineralization, Remineralization and Dental Cavity, sponsored by Colgate Palmolive. Completed at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 82 studies in Dental Caries with a site in Brazil — 5 open to participants now, 6 under way, none of them phase 3. Dental Caries · Brazil.

Enrollment
60th of 79
36 · median 119
Started
2025
with 1 other
Phase 3
6 of 82
none open now
Registered
80th of 82
by date

Among the 82 studies in Dental Caries with a site in Brazil, this one is the 60th largest by enrollment of the 79 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 80th registered.

Dental Caries

1,175 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

5 of the 82 studies in Dental Caries with a site in Brazil are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Dental Caries with a site in Brazil, or all of them as a file.
02

Study summary

Clinical study to evaluate the anti-cavity effectiveness of three dentrifices using an intra-oral enamel Demineralization and Remineralization In-Situ Model. This is a six-week duration, Phase III, single-center, triple-blind crossover study. Thirty-six healthy adults will be randomly allocated to three groups for the treatment phases, which are interspersed with washout periods.

Read the detailed description

This Phase III, randomized, triple-blind, crossover study will assess the anti-cavity effectiveness of three different dentrifices. Thirty-six participants, aged 18-70, will use an intra-oral appliance. For six weeks, they will be divided into three treatment groups and instructed to brush twice daily with one of the following: one using a fluoride-free toothpaste with a chalk base and herbal ingredients, another using a fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base, and a negative control group using a fluoride-free toothpaste in a PCC/RNCC base. Each participant will receive a soft-bristle toothbrush and the toothpastes assigned.

Between each five-day treatment phase, participants will have a nine-day washout period, using a fluoride-free toothpaste in a PCC/RNCC base. The study's eight-visit schedule includes a baseline visit, three treatment phases, three washout periods interspersed between the treatment phases, and a final visit. The primary outcome will be the measurement of changes in enamel microhardness, with assessments taking place both before and after each treatment to determine the impact on the enamel. The expected outcome is the confirmation of the alternative hypothesis, which predicts a reduction in the percentage of mineral loss from the surface of bovine enamel after using dentifrices containing 1000 ppm MFP with 1.5% arginine or herbal ingredients for five days each, compared to the control group. The percentage of mineral loss on the tooth surface relative to baseline will be used to quantify the extent of reduction in enamel demineralization. A two factor ANCOVA using the baseline as the covariate will be conducted to determine if a significant treatment effect exists. Adverse events and compliance will be closely monitored, with strict confidentiality maintained for all participants.

03

Conditions studied

  • Demineralization
  • Remineralization
  • Dental Cavity
  • Enamel Lesions

Browse trials for

Keywords

  • enamel mircrohardness
  • enamel demineralization-remineralization
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Potential subjects must meet ALL of the following criteria:

  • Males and females, between 18-70 years of age (inclusive);
  • Form signed and availability for the duration of the study;
  • Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study. Examples include heart problems, valve/hip replacements, etc);
  • Willingness to provide information related to their medical history;
  • Minimum of 20 uncrowned permanent natural teeth (excluding third molars); Normal salivary flow;
  • Willingness to wear an intra-oral appliance all day as instructed except when eating and drinking.

Exclusion Criteria: Potential subjects must NOT HAVE ANY of the following conditions:

  • Oral pathology, chronic disease, or a history of allergy to testing products;
  • Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study;
  • Subject participating in any other clinical study;
  • Subject pregnant or breastfeeding;
  • Subject allergic to oral care products, personal care consumer products, or their ingredients;
  • Extended use of antibiotics or therapeutic mouthwash any time during the three months prior to entry into the study;
  • A medical history reporting that the subject has a current systemic or disease, such as diabetes, lupus, etc.;
  • Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine);
  • Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). Pocket depth equal or greater than 4 mm;
  • Five or more decayed, untreated dental sites (cavities);
  • Current smokers and subjects with a history of alcohol or drug abuse;
  • Dental work prevents wearing of the appliance or a reported need to wear a night guard.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Test Group

    Subjects will brush using a fluoride free toothpaste in a chalk base with herbal ingredients and a soft bristle toothbrush

    Drug: Fluoride free toothpaste in a chalk base · Device: Toothbrush

  • Active comparator
    Positive Control Group

    Subjects will brush using a fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base and a soft bristle toothbrush

    Drug: Fluoride Toothpaste · Device: Toothbrush

  • Sham comparator
    Negative Control Group

    Subjects will brush using a fluoride free toothpaste in a PCC/RNCC base and a soft bristle toothbrush

    Drug: Fluoride free toothpaste in a PCC/RNCC base · Device: Toothbrush

  • Other
    Washout Group

    Subjects will brush using a fluoride free toothpaste in a PCC/RNCC base and a soft bristle toothbrush for 9 days, between the treatment phases.

    Drug: Fluoride free toothpaste in a PCC/RNCC base · Device: Toothbrush

Interventions

  • DrugFluoride free toothpaste in a chalk base

    Fluoride free toothpaste in a chalk base with herbal ingredients

  • DrugFluoride Toothpaste

    Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base

  • DrugFluoride free toothpaste in a PCC/RNCC base

    Fluoride free toothpaste in a PCC/RNCC base

  • DeviceToothbrush

    A commercially available adult soft bristle toothbrush

06

What researchers measure

Primary outcomes

  1. Microhardness change

    The primary outcome of this study will be the change in the hardness of an intra-oral appliance before and after treatment. It will be determined by measuring the length of an indentation made on the appliance, which in turn allows for the calculation of its hardness value. The effectiveness of the treatment in reducing enamel demineralization by quantifying the percentage of mineral loss relative to the baseline will also be assessed.

    Time frame: 6 weeks

07

Study locations

1 site
  • Federal University of Alagoas
    Maceió, Alagoas 57072-970, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

Of 18 phase 3 interventional studies under Dental Caries, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 26. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Oct 9, 2025
Primary completionActual
Dec 11, 2025
CompletionActual
Dec 11, 2025
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134231
Lead sponsor
Colgate Palmolive
Collaborators
Federal University of Alagoas
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Oct 9, 2025
Primary completion
Dec 11, 2025
Completion
Dec 11, 2025
Last update
Feb 6, 2026

Study contacts

Natanael Santos, PhD
principal investigator · Federal University of Alagoas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion